European Urology Open Science最新文献

{"title":"Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy","authors":"Joep J. de Jong ,&nbsp;James A. Proudfoot ,&nbsp;Siamak Daneshmand ,&nbsp;Robert S. Svatek ,&nbsp;Vikram Narayan ,&nbsp;Elai Davicioni ,&nbsp;Shreyas Joshi ,&nbsp;Aaron Dahmen ,&nbsp;Roger Li ,&nbsp;Brant A. Inman ,&nbsp;Paras Shah ,&nbsp;Iftach Chaplin ,&nbsp;Jonathan Wright ,&nbsp;Ewan A. Gibb ,&nbsp;Yair Lotan","doi":"10.1016/j.euros.2024.12.009","DOIUrl":"10.1016/j.euros.2024.12.009","url":null,"abstract":"<div><h3>Background and objective</h3><div>Many patients with bladder cancer are understaged. Previous work revealed that molecular subtyping using Decipher Bladder improves clinical staging. This multicenter validation study evaluated Decipher Bladder for upstaging in patients who underwent radical cystectomy (RC) without neoadjuvant therapy.</div></div><div><h3>Methods</h3><div>The Decipher Bladder genomic subtyping classifier (GSC; Veracyte, San Diego, CA, USA) was performed on bladder tumor specimens from patients with high-grade, clinically organ-confined (cTa-T2N0M0) urothelial carcinoma who subsequently underwent RC without neoadjuvant chemotherapy. The primary endpoint was pathological upstaging to non–organ-confined (NOC) disease (pT3+ and/or N+) at RC. The secondary endpoints included overall survival (OS) and pathological upstaging to MIBC+ disease (pT2+ and/or N+) at RC within clinically non–muscle-invasive bladder cancer (cNMIBC) cases.</div></div><div><h3>Key findings and limitations</h3><div>A total of 226 patients (134 cNMIBC [cTa/Tis/T1] and 92 cT2) were analyzed from eight participating institutions. Upstaging to NOC disease was observed in 33% of patients (19% for cNMIBC and 53% for cT2). Molecular subtyping identified 138 luminal and 88 nonluminal tumors. Rates of upstaging to NOC were 41% in nonluminal and 28% in luminal tumors (univariable <em>p</em> = 0.04), which was not independently significant after adjusting for clinical variables. Upstaging to MIBC+ in cNMIBC patients was lower in luminal versus nonluminal tumors (32% vs 51%, multivariable <em>p</em> = 0.03). Patients with nonluminal tumors had worse OS on multivariable analyses (<em>p</em> &lt; 0.05). Limitations include retrospective design and sample size.</div></div><div><h3>Conclusions and clinical implications</h3><div>Luminal tumors represent less aggressive disease, reflected by lower rates of pathological upstaging and favorable OS with RC compared with nonluminal tumors.</div></div><div><h3>Patient summary</h3><div>Molecular subtyping suggests that in clinically non–muscle-invasive bladder cancer, luminal tumors harbor less aggressive disease, as reflected by lower rates of pathological upstaging to muscle-invasive disease and favorable outcomes with radical cystectomy, in comparison with nonluminal bladder cancer.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"73 ","pages":"Pages 24-30"},"PeriodicalIF":3.2,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Two Cardiovascular Health Algorithms and Kidney Stones: A Nationwide Cross-sectional Study","authors":"Shan Yin ,&nbsp;Zhenzhen Yang ,&nbsp;Pingyu Zhu ,&nbsp;Xuesong Yang ,&nbsp;Xiaodong Yu ,&nbsp;Tielong Tang ,&nbsp;Yan Borné","doi":"10.1016/j.euros.2025.01.003","DOIUrl":"10.1016/j.euros.2025.01.003","url":null,"abstract":"<div><h3>Background and objective</h3><div>There is limited literature on the relationship between cardiovascular health (CVH) and kidney stones. This study aims to compare the association of Life’s Simple 7 (LS7) and Life’s Essential 8 (LE8) with kidney stone prevalence.</div></div><div><h3>Methods</h3><div>A cross-sectional analysis was conducted utilizing NHANES data (2007–2018). Participants aged ≥20 yr with a history of kidney stones and available LS7 and LE8 scores were included. Both LS7 and LE8 are scored such that higher scores indicate better CVH. Weighted proportions and multivariable logistic regression models assessed the relationship between CVH metrics and kidney stone prevalence, adjusting for confounders. The receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC) were determined to distinguish between LS7 and LE8 in terms of their discriminative ability within the model associated with kidney stones.</div></div><div><h3>Key findings and limitations</h3><div>A total of 23 563 adults were included; the mean age was 48.1 yr (48.1% male). Kidney stone prevalence was 10.1%. The mean LS7 and LE8 scores were 8.4 and 68.6, respectively. A multivariate analysis and the restricted cubic spline model indicated a significant nonlinear negative correlation between these CVH measures and kidney stone prevalence. The LS7 ideal group showed a lower prevalence than the poor group (odds ratio [OR] = 0.53; 95% confidence interval [CI] 0.41–0.69). The high CVH group had a lower prevalence than the low CVH group (OR = 0.46; 95% CI 0.36–0.57). The AUCs for evaluating LS7 and kidney stones, as well as for LE8 and kidney stones were 0.676 and 0.677, respectively. Limitations were as follows: cross-sectional design limiting causal inference, recall bias from self-reported data, and potential residual confounding.</div></div><div><h3>Conclusions and clinical implications</h3><div>Both CVH algorithms show a significant nonlinear negative correlation with kidney stone prevalence. LS7 may be more accessible for broader implementation. Further high-quality prospective studies are needed to clarify this relationship.</div></div><div><h3>Patient summary</h3><div>In this study, we explored the connection between heart health and kidney stones using data from a large national survey. We found that better heart health, measured by two different scoring methods, is linked to a lower chance of having kidney stones. Our results suggest that promoting heart health could help reduce the risk of kidney stones in adults.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"73 ","pages":"Pages 8-16"},"PeriodicalIF":3.2,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omission of Contralateral Systematic Biopsies in Unilateral Suspicious Prostate Cancer on Magnetic Resonance Imaging: Implications for Radiation Treatment Selection","authors":"Daniël L. van den Kroonenberg ,&nbsp;Sanne J. Jonker ,&nbsp;Auke Jager ,&nbsp;Joëlle D. Stoter ,&nbsp;Eva Schaake ,&nbsp;Karel A. Hinnen ,&nbsp;Wietse S.C. Eppinga ,&nbsp;Ivo G. Schoots ,&nbsp;Jochem R.N. van der Voort van Zyp ,&nbsp;André N. Vis","doi":"10.1016/j.euros.2025.01.006","DOIUrl":"10.1016/j.euros.2025.01.006","url":null,"abstract":"<div><h3>Background and objective</h3><div>A combined approach of magnetic resonance imaging (MRI) targeted biopsies (TBx) and systematic biopsies (SBx) was recommended previously in patients with unilateral suspicious prostate cancer (PCa) on MRI. Yet, new PCa guidelines suggest that contralateral SBx can be omitted. It is unknown how this guideline modification impacts treatment selection. This study evaluates the value of contralateral SBx in radiation treatment selection in patients with unilateral suspicious lesions (Prostate Imaging Reporting and Data System [PI-RADS] ≥3) on MRI.</div></div><div><h3>Methods</h3><div>Case files of 80 patients with a unilateral suspicious lesion on diagnostic MRI who underwent TBx and bilateral SBx were collected. The cases were presented to four radiation oncologists twice: once with diagnostic information of bilateral SBx and TBx, and once with diagnostic information of ipsilateral SBx and TBx pathology results. Based on this information, external beam radiation treatment (EBRT) fractionation scheme, duration of androgen deprivation therapy (ADT), and feasibility of brachytherapy (monotherapy or brachyboost) were considered.</div></div><div><h3>Key findings and limitations</h3><div>After omitting information of contralateral SBx pathology results, selection of EBRT fractionation scheme and ADT duration changed in 14% (95% confidence interval [CI] 9.8–17) and 15% (95% CI 11–19) of cases, respectively. The feasibility of brachytherapy as monotherapy and brachyboost, respectively, changed in 11% (95% CI 7.9–15) and in 21% (95% CI 17–26) of cases, with overall poor interobserver variability for both diagnostic scenarios (Fleiss’ kappa 0.15 and 0.16).</div></div><div><h3>Conclusions and clinical implications</h3><div>Our findings indicate that omitting contralateral SBx has an impact on the treatment selection of patients who choose for radiation therapy as their treatment for locally confined PCa.</div></div><div><h3>Patient summary</h3><div>In patients with prostate cancer identified via magnetic resonance imaging on one side of the prostate, exclusion of prostate biopsies from the opposite side affected the selection of radiation treatment.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"73 ","pages":"Pages 17-23"},"PeriodicalIF":3.2,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Prebiopsy Multiparametric Magnetic Resonance Imaging on Prostate Cancer Detection in Switzerland","authors":"Thomas Paul Scherer ,&nbsp;Dominik Menges ,&nbsp;Uwe Bieri ,&nbsp;Lea Wildisen ,&nbsp;Katharina Staehelin ,&nbsp;Daniel Eberli ,&nbsp;Sabine Rohrmann ,&nbsp;Cédric Poyet","doi":"10.1016/j.euros.2025.01.004","DOIUrl":"10.1016/j.euros.2025.01.004","url":null,"abstract":"<div><h3>Background and objective</h3><div>Multiparametric magnetic resonance imaging (mpMRI)-guided prostate biopsies have become the standard of care. This study aims to analyze changes in the distribution of detected prostate cancer (PCa) risk groups in Switzerland during the adoption period of a multiparametric magnetic resonance imaging (mpMRI)-guided prostate biopsy.</div></div><div><h3>Methods</h3><div>This ecological study analyzed prostate biopsies from a tertiary hospital and PCa diagnoses from the National Agency for Cancer Registration in Switzerland between January 2005 and December 2019. A survey assessed mpMRI uptake in Swiss urological centers. PCa risk group proportions were calculated and compared for the entire period and annually.</div></div><div><h3>Key findings and limitations</h3><div>A total of 4890 biopsies in the hospital dataset and 74 747 national PCa cases were analyzed. Before mpMRI availability, 72.6% of hospital biopsies were PCa negative, with detected cases including 46.4% low risk (LR), 30.5% intermediate risk (IR), and 23.2% high risk (HR). After the availability of mpMRI, 45.7% were PCa negative, with 24.6% LR, 49.0% IR, and 26.5% HR. National mpMRI uptake began in 2008, surpassing 95% by 2019. In 2005, 3448 PCa cases were recorded across 14 cantons, with 46.3% LR, 33.1% IR, and 20.6% HR. By 2019, 6868 cases were registered in 23 cantons, with 28.0% LR, 48.9% IR, and 23.2% HR.</div></div><div><h3>Conclusions and clinical implications</h3><div>After implementation of mpMRI, fewer negative prostate biopsy results were observed. Furthermore, a shift was detected in the distribution of risk groups, with an increase in the proportion of IR cases and a decline in LR cases alongside the uptake of mpMRI. The proportion of HR cases remained essentially constant over time. Further research is needed to determine whether this reflects improved stratification or an artifact of the changed diagnostic pathway.</div></div><div><h3>Patient summary</h3><div>In this study, we examined how the detected prostate cancer grades changed during the adoption of multiparametric magnetic resonance imaging (mpMRI)-guided prostate biopsies in Switzerland between 2005 and 2019. After mpMRI, fewer negative biopsies occurred and the distribution of prostate cancer grades changed, with more intermediate-risk and fewer low-risk cancers identified, while high-risk cases remained stable.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"73 ","pages":"Pages 1-7"},"PeriodicalIF":3.2,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Detection Rates for Prostate-specific Membrane Antigen–avid Prostate Cancer Recurrence at Low Prostate-specific Antigen levels on Extended Axial Field-of-view Positron Emission Tomography/Computed Tomography","authors":"Sarah Thomas ,&nbsp;Jason Callahan ,&nbsp;Paul Conway ,&nbsp;Daniel Moon ,&nbsp;Hugh Morgan ,&nbsp;Johanna Ingbritsen ,&nbsp;Melissa Munro ,&nbsp;Robert E. Ware ,&nbsp;Phil Dundee ,&nbsp;Rodney J. Hicks","doi":"10.1016/j.euros.2024.11.008","DOIUrl":"10.1016/j.euros.2024.11.008","url":null,"abstract":"<div><h3>Background and objective</h3><div>Although prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has impacted the investigation and management of biochemical recurrence (BCR) of prostate cancer, negative scans are common at low rising prostate-specific antigen (PSA) levels. PET/CT devices with an extended axial field-of-view, such as the Siemens Biograph Vision Quadra (Quadra) scanner, have substantially higher sensitivity than conventional field-of-view scanners. Our aim was to assess whether the enhanced signal-to-noise ratios achieved on the Quadra scanner improve detection of low-volume disease and thereby increase detection of PC at low PSA levels.</div></div><div><h3>Methods</h3><div>We analysed data for the first 300 consecutive patients who underwent clinically indicated PSMA PET/CT for BCR using a Quadra scanner. We assessed scan positivity and the location of detected disease by PSA category.</div></div><div><h3>Key findings and limitations</h3><div>The positivity rate increased with the PSA level from 67% for PSA &lt;0.2 ng/ml to &gt;90% for PSA &gt;1.0 ng/ml (<em>p</em> &lt; 0.05). Disease location also differed by PSA category, with prostate bed recurrence alone identified in 63% of positive cases with PSA &lt;0.2 ng/ml, but &lt;25% of cases with PSA &gt;1.0 ng/ml, and distant metastases present in only 6% of positive cases with PSA &lt;0.2 ng/ml versus &gt;40% of cases with PSA &gt;1.0 ng/ml. In the group with PSA &lt;0.2 ng/ml, pelvic nodal disease without local recurrence was identified in 31% of cases.</div></div><div><h3>Conclusions and clinical implications</h3><div>In comparison to literature data, the Quadra scanner has substantially higher positivity rates at very low PSA levels. At these levels, disease was largely confined to the pelvis and potentially amenable to salvage radiotherapy. However, more than one-third of these patients had disease exclusively outside the prostate bed, with implications for the efficacy and morbidity of current salvage radiotherapy approaches.</div></div><div><h3>Patient summary</h3><div>We investigated a new PET/CT scanner (positron emission tomography/computed tomography) for detection of prostate cancer recurrence. This more sensitive scanner had a higher detection rate, particularly for patients with low PSA (prostate-specific antigen) in their blood. Our results suggest that the new scanner can detect disease recurrence earlier and more accurately than standard PET/CT scanners, which can help in planning further treatment.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 49-56"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"9 Office-based MRI fusion cryoablation: Impact on PCa treated natural history","authors":"Martínez Salamanca J.I.,&nbsp;W Kattan M.W.K.,&nbsp;Egui-Benatouil G, Maiolino G.,&nbsp;Shafizadeh F.,&nbsp;Bianco Jr F.J.","doi":"10.1016/S2666-1683(25)00040-0","DOIUrl":"10.1016/S2666-1683(25)00040-0","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages S9-S10"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143141049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"20 Ablation of recurrent bladder tumors by cold plasma - First in human study","authors":"Dotan Z.,&nbsp;Luder A.L.,&nbsp;Mahmud H.M.,&nbsp;Kleinmann N.K.,&nbsp;Perezb D.F.,&nbsp;Dothanb D.D.,&nbsp;Rosenzweig B.R.,&nbsp;Chertin B.C.,&nbsp;Laufer M.L.","doi":"10.1016/S2666-1683(25)00024-2","DOIUrl":"10.1016/S2666-1683(25)00024-2","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S23"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Additional Active Treatment for Prostate Cancer on Health-related Quality of Life of Men: Results from the EUPROMS 2.0 1-year Follow-up Survey","authors":"Lionne D.F. Venderbos ,&nbsp;Sebastiaan Remmers ,&nbsp;André Deschamps ,&nbsp;John Dowling ,&nbsp;Ernst-Günter Carl ,&nbsp;Nuno Pereira-Azevedo ,&nbsp;Monique J. Roobol","doi":"10.1016/j.euros.2024.11.006","DOIUrl":"10.1016/j.euros.2024.11.006","url":null,"abstract":"<div><h3>Background and objective</h3><div>In 2019 and 2021, Europa Uomo initiated the Europa Uomo Patient Reported Outcome Study (EUPROMS) and the EUPROMS 2.0 survey, with the goal of collecting data on patients’ self-reported perspective on physical and mental well-being outside of a clinical trial setting, to be able to investigate the burden of prostate cancer (PCa) treatment from a patient-to-patient perspective. Acknowledging the importance of collecting quality of life (QoL) follow-up data, a 1-yr follow-up (1yrFU) study was conducted to assess the effect of additional PCa treatment on QoL.</div></div><div><h3>Methods</h3><div>Men with PCa who participated in the EUPROMS 2.0 survey and indicated that they were open to collection of a follow-up measurement were reinvited to complete the 1yrFU survey. The EUPROMS 2.0 1yrFU survey included the validated European Quality of Life 5 Dimension 5 Level (EQ-5D-5L), European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30), Expanded Prostate Cancer Index Composite Short Form (EPIC-26), and International Index of Erectile Function (IIEF)-15 overall satisfaction domains. Descriptive statistics were used to assess demographic characteristics and to analyze the patient-reported outcome data.</div></div><div><h3>Key findings and limitations</h3><div>A total of 1006 (54%) men completed the survey. The median age at the time of questionnaire completion was 72 yr (interquartile range 66–76 yr). Of them, 641 men (64%) underwent no new treatment, while 365 men (36%) underwent new treatment, including 247 (247/365, 68%) for PCa. In total, 114 patients (46%) underwent new androgen deprivation therapy (ADT) and 81 (33%) new external beam radiotherapy (EBRT). It is indicated that the impact of new ADT and EBRT on sexual function is immediate and detrimental, and continues to last over time. However, for men who underwent EBRT or radical prostatectomy earlier and did not undergo new treatment, slight improvements on various domains are reported.</div></div><div><h3>Conclusions and clinical implications</h3><div>The EUPROMS 2.0 1yrFU study provides additional information on treatments that are already in common use and will help future PCa patients to make informed and shared decisions on PCa treatment.</div></div><div><h3>Patient summary</h3><div>The follow-up data on quality of life collected by Europa Uomo can be used to inform future prostate cancer (PCa) patients about the impact of undergoing (multiple) PCa treatment(s).</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 114-124"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Overview of Patient-reported Outcomes for Men with Prostate Cancer: Results from the PIONEER Consortium","authors":"Sebastiaan Remmers ,&nbsp;Katharina Beyer ,&nbsp;Tariq A. Lalmahomed ,&nbsp;Peter Prinsen ,&nbsp;Nicole J.E. Horevoorts ,&nbsp;Nora Tabea Sibert ,&nbsp;Christoph Kowalski ,&nbsp;Francesco Barletta ,&nbsp;Oliver Brunckhorst ,&nbsp;Giorgio Gandaglia ,&nbsp;Jochem R.N. van der Voort van Zyp ,&nbsp;Emma J. Smith ,&nbsp;Andre Deschamps ,&nbsp;Laurence Collette ,&nbsp;Philip Cornford ,&nbsp;Susan Evans-Axelsson ,&nbsp;James N’Dow ,&nbsp;Mieke Van Hemelrijck ,&nbsp;Monique J. Roobol ,&nbsp;Lionne D.F. Venderbos","doi":"10.1016/j.euros.2024.11.009","DOIUrl":"10.1016/j.euros.2024.11.009","url":null,"abstract":"<div><h3>Background and objective</h3><div>Patient-reported outcome measures (PROMs) are increasingly being used to capture the patients’ perspective of their functional status and quality of life (QoL). Big data can help us better understand patient-reported outcomes (PROs). Using prospectively collected data from the Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) consortium, we aimed to describe the functional status and QoL in men with prostate cancer (PCa) treated with active surveillance (AS), radical prostatectomy (RP), and radiotherapy (RT), and to demonstrate the applicability of PROM data on a large scale and at a European level.</div></div><div><h3>Methods</h3><div>We identified data sources that collected QoL data using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-PR25, or Expanded Prostate Cancer Index Composite (EPIC)-26/50 questionnaires. Aggregated summary scores for urinary, bowel, and sexual dysfunction, global health status, and QoL were shared for each data source.</div></div><div><h3>Key findings and limitations</h3><div>We identified eight data sources originating from various settings: routine hospital data, embedded research PRO collection, survey data collected by a patient organization, multi-institutional prospective cohort study, and registry data. PRO data were available for 709 men on AS, 20 508 on RP, and 3417 on RT, with a median time between diagnosis and PROM assessment ranging from 1 to 8.7 yr. Most men were diagnosed with Gleason ≤7 disease, and T1 or T2 PCa. We observed that sexual dysfunction was the most affected PRO and found large differences between data sources.</div></div><div><h3>Conclusions and clinical implications</h3><div>Our results support the feasibility of PRO assessment using big data in Europe. Implementation of PROMs in clinical practice and the use of standardized methods could improve value-based health care provision.</div></div><div><h3>Patient summary</h3><div>In this study, we combined several data sources that reported urinary, bowel, and sexual dysfunction, global health status, and quality of life. We identified eight data sources and show that sexual function is the most affected domain after treatment.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 106-113"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copyright page","authors":"","doi":"10.1016/S2666-1683(25)00005-9","DOIUrl":"10.1016/S2666-1683(25)00005-9","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page I"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143092597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}